Bausch + Lomb (eye care)
eröffnet am 04.08.22 15:30:30 von
neuester Beitrag 02.11.23 12:16:11 von
neuester Beitrag 02.11.23 12:16:11 von
Beiträge: 7
ID: 1.362.513
ID: 1.362.513
Aufrufe heute: 1
Gesamt: 1.685
Gesamt: 1.685
Aktive User: 0
ISIN: CA0717051076 · WKN: A3DLMS · Symbol: BLCO
14,700
USD
-2,78 %
-0,420 USD
Letzter Kurs 20:08:12 NYSE
Neuigkeiten
29.04.24 · Business Wire (engl.)  |
25.04.24 · Business Wire (engl.) |
18.04.24 · Business Wire (engl.) |
15.04.24 · Business Wire (engl.) |
27.03.24 · Business Wire (engl.) |
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,9700 | +324,79 | |
| 1,7400 | +74,00 | |
| 16,190 | +47,18 | |
| 2,9700 | +20,73 | |
| 6,9900 | +19,90 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,1500 | -15,48 | |
| 1,7200 | -15,69 | |
| 0,5700 | -16,60 | |
| 0,5800 | -17,14 | |
| 1,8819 | -55,93 |
Beitrag zu dieser Diskussion schreiben
Feedback
Q3: Bausch + Lomb zuletzt wohl auch mit einer erhöhten Guidance: https://ir.bauschhealth.com/news-releases
...
...
...
...
Antwort auf Beitrag Nr.: 74.468.031 von faultcode am 12.09.23 14:00:54https://ir.bauschhealth.com/news-releases
Bausch Health’s Bausch + Lomb Announces Completion of the Acquisition of XIIDRA®
LAVAL, Quebec, September 29, 2023 – Bausch + Lomb Corporation (“Bausch + Lomb”) (NYSE/TSX: BLCO), a subsidiary of Bausch Health Companies Inc. (the “Company” or “Bausch Health”) (NYSE/TSX: BHC), today announced it has completed its acquisition of XIIDRA® (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalmology assets.
...
Bausch Health’s Bausch + Lomb Announces Completion of the Acquisition of XIIDRA®
LAVAL, Quebec, September 29, 2023 – Bausch + Lomb Corporation (“Bausch + Lomb”) (NYSE/TSX: BLCO), a subsidiary of Bausch Health Companies Inc. (the “Company” or “Bausch Health”) (NYSE/TSX: BHC), today announced it has completed its acquisition of XIIDRA® (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalmology assets.
...
11.9.
Banks Launch $1.9 Billion Debt Sale for Bausch + Lomb’s Acquisition from Novartis
https://finance.yahoo.com/news/banks-launch-1-9-billion-2004…
...
A group of banks led by JPMorgan Chase & Co. is selling a $1.9 billion bond-and-loan deal to support Bausch + Lomb Corp.’s acquisition of a portfolio of eye medicines from Novartis AG.
...
The proceeds will finance the purchase of Xiidra, a non-steroid eye drop that treats symptoms of dry eye disease, as well as other ophthalmology assets from Novartis, the people said, asking not to be named discussing a private transaction.
...
Banks Launch $1.9 Billion Debt Sale for Bausch + Lomb’s Acquisition from Novartis
https://finance.yahoo.com/news/banks-launch-1-9-billion-2004…
...
A group of banks led by JPMorgan Chase & Co. is selling a $1.9 billion bond-and-loan deal to support Bausch + Lomb Corp.’s acquisition of a portfolio of eye medicines from Novartis AG.
...
The proceeds will finance the purchase of Xiidra, a non-steroid eye drop that treats symptoms of dry eye disease, as well as other ophthalmology assets from Novartis, the people said, asking not to be named discussing a private transaction.
...
!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: Lõschung auf Wunsch des Users
3.5.
Bausch + Lomb Announces First-Quarter 2023 Results and Provides 2023 Guidance
https://www.wallstreet-online.de/nachricht/16879620-bausch-l…
...
2023 Financial Outlook4
Bausch + Lomb provided guidance for the full year of 2023, as follows:
• Full-year revenue range of $3.90 – $3.95 billion, reflecting anticipated growth of 5-6% on a constant currency basis1
• Full-year Adjusted EBITDA (non-GAAP)1 range of $700 – $750 million
• $760 million at the mid-point of the full-year Adj. EBITDA (non-GAAP) guidance range, adjusted for currency headwinds1
• Foreign exchange revenue and Adjusted EBITDA (non-GAAP)1 headwinds expected to be approximately $50 million and $35 million for the full year, respectively
...
Bausch + Lomb Announces First-Quarter 2023 Results and Provides 2023 Guidance
https://www.wallstreet-online.de/nachricht/16879620-bausch-l…
...
2023 Financial Outlook4
Bausch + Lomb provided guidance for the full year of 2023, as follows:
• Full-year revenue range of $3.90 – $3.95 billion, reflecting anticipated growth of 5-6% on a constant currency basis1
• Full-year Adjusted EBITDA (non-GAAP)1 range of $700 – $750 million
• $760 million at the mid-point of the full-year Adj. EBITDA (non-GAAP) guidance range, adjusted for currency headwinds1
• Foreign exchange revenue and Adjusted EBITDA (non-GAAP)1 headwinds expected to be approximately $50 million and $35 million for the full year, respectively
...
Trading Spotlight
15.2.
Bausch + Lomb Appoints Brent Saunders as Chief Executive Officer and Chair of the Board of Directors, Effective March 6, 2023
https://www.wallstreet-online.de/nachricht/16564025-bausch-l…
...
Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, announced the appointment of Brent Saunders as chief executive officer (“CEO”) and chair of the Board of Directors (“Board”) of the Company, effective March 6, 2023.
Concurrent with this appointment, and as previously announced, Joseph C. Papa will step down from his roles as CEO and director. Additionally, effective upon Mr. Saunders’ appointment as chair of the Board, Thomas W. Ross, Sr. will become the Lead Independent Director of the Board.
To facilitate an orderly transition, Mr. Saunders will join Bausch + Lomb on Feb. 16, 2023, in an advisory capacity, where he will work closely with Mr. Papa.
Mr. Saunders will return to Bausch + Lomb after having served at the Company as CEO from 2010 to 2013. In total, he brings more than 25 years of leadership in health care, having served in president, CEO and chairman roles, among others, at several global pharmaceutical and health care companies, including Schering-Plough Corporation, Forest Laboratories Inc., Actavis plc, Allergan plc and The Beauty Health Company.
...
=> +9%
Bausch + Lomb Appoints Brent Saunders as Chief Executive Officer and Chair of the Board of Directors, Effective March 6, 2023
https://www.wallstreet-online.de/nachricht/16564025-bausch-l…
...
Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, announced the appointment of Brent Saunders as chief executive officer (“CEO”) and chair of the Board of Directors (“Board”) of the Company, effective March 6, 2023.
Concurrent with this appointment, and as previously announced, Joseph C. Papa will step down from his roles as CEO and director. Additionally, effective upon Mr. Saunders’ appointment as chair of the Board, Thomas W. Ross, Sr. will become the Lead Independent Director of the Board.
To facilitate an orderly transition, Mr. Saunders will join Bausch + Lomb on Feb. 16, 2023, in an advisory capacity, where he will work closely with Mr. Papa.
Mr. Saunders will return to Bausch + Lomb after having served at the Company as CEO from 2010 to 2013. In total, he brings more than 25 years of leadership in health care, having served in president, CEO and chairman roles, among others, at several global pharmaceutical and health care companies, including Schering-Plough Corporation, Forest Laboratories Inc., Actavis plc, Allergan plc and The Beauty Health Company.
...
=> +9%
DurchsuchenBeitrag schreiben
